unknown
Stage
1
Investors
About
28bio develops human-derived brain and peripheral nerve organoid platforms (Brain-on-a-Chip and Nerve-on-a-Chip) and delivers associated services to enable neurotoxicity, efficacy, and disease modeling for pharmaceutical research. Their CNS-3D and PNS-3D products provide functional assays for seizure liability, neuroinflammation, myelination, and Alzheimer’s disease.
Explore 28bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.